Atlas Trials

Camrelizumab Combined With Famitinib Malate for Treatment of Recurrent/Metastatic Cervical Cancer

Clinical trial NCT04906993 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT04906993
Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Cervical Cancer
Start date
2021-07-23
Primary completion
2025-06-10
Enrollment
443

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.